Prevention of HIV in injecting drug addicts. What has been done - What could be better?;HIV-Prävention bei Drogenkonsumenten : Was haben wir gemacht - was könnten wir besser machen?

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 50, Issue 4, 2007, Pages 465-470

  Gölz, Jörg ^a,b  

^a Praxiszentrum Kaiserdamm   (Germany)

^b Praxiszentrum Kaiserdamm Berlin ^*  (Germany)

Author keywords

Harm reduction; HCV; IDU; Prevention of HIV

Indexed keywords

ARTICLE; COMORBIDITY; EPIDEMIC; GERMANY; HEALTH CARE DELIVERY; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; ORGANIZATION AND MANAGEMENT; STATISTICS; SUBSTANCE ABUSE;

COMORBIDITY; DELIVERY OF HEALTH CARE; DISEASE OUTBREAKS; GERMANY; HEALTH PROMOTION; HIV INFECTIONS; HUMANS; INCIDENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34247523654     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-007-0188-8     Document Type: Article

References (25)

1. Köhler H, Lange W, Vettermann W et al. (1985) Untersuchung auf LAV/HTLV-III-Antikörper bei Insassen Berliner Haftanstalten mit Hepatitis-Risiko. Bundesgesundheitsblatt 28:328-329
2. Battjes RJ, Pickens R (1988) HIV Infection among intravenous drug abusers (IVDAs) in five U.S. Cities. IV th International Conference on AIDS, Stockholm, Abstr. 4523
3. Hawks D, Lenton S (1995) Harm reduction in Australia: has it worked? A review. Drug Alcohol Rev 14:291-304
4. Gölz J (2006) Deutsche Gesellschaft für Suchtmedizin e.V. Entstehungsgeschichte. Hepatitis More 1:30-31
5. Commonwealth Department of Health and Ageing (2002) Health Outcomes International Return on investment in needle and syringe programs in Australia. Canberra. http://www.health.gov.au/pubhlth/publicat/document/roireport.pdf
6. General Accounting Office (1993) Needle exchange programs: research suggests promise as an AIDS prevention strategy. US Government Printing Office, Washington DC
7. Hurley SF, Jolley DJ, Kaldor JM (1997) Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 349:1797-1800
8. Coyle SL, Needle RH, Normand J (1998) Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Reports 113(Suppl 1):19-30
9. Tinsman PD, Bullman S, Chen X et al. (2001) Factors affecting client response to HIV outcome efforts. J Substance Abuse 13:201-214
10. Dole VP, Nyswander ME (1965) Treatment for diacetylmorphine (Heroin) Addiction. JAMA 193:646-650
11. WHO/UNODC/UNAIDS (2004) Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. WHO, Geneva
12. Metzger DS, Woody GE, McLellum AT et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out of treatment: an 18 month prospective follow-up. J Acqir Immun Defic Syndr 6:1049-1056
13. Evaluating the effectiveness of addiction treatment: reasonable expectations, appropriate comparisons. Milbank Quarterly 1996;74:51-85
14. Gossop M, MarsdenJ, Stewart D, Kidd T (2003) The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction 98:291-303
15. Gölz J et al. (2002) Impact of different HAART regimes on adherence and durability of treatment The Kaiserdamm Cohort XIV Int. AIDS Conference, Barcelona, July 7-12, Abstr. WePeB5838
16. Backmund M, Hinrichsen H, Rossol S et al. (2006) Leitlinien der Deutschen Gesellschaft für Suchtmedizin (DGS e.V.): Therapie der chronischen Hepatitis C bei intravenös Drogengebrauchem. Suchtmed 8:129-133
17. Wood E, Montaner JS, Yip B et al. (2003) Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medicalk Association J 169:656-661
18. de Ridder M, Dettmer K, Hackenberg B, Leicht A (2004) Hepatitisimpfung auf offenen Drogenszenen. Dtsch Ärztebl 101:2893-2896
19. Lines R, Jürgens R, Betteridge G et al. (2006) Prison needle exchange: lessons from a comprehensive review of international evidence and experience. Canadian HIV/AIDS Legal Network, 2nd edn. ISBN 1-896735-52-5
20. Pompidou Group (2002) Principles for working with prisoners who are (or have been) misusing drugs. In: Prison, Drugs and Society. Council of Europe Publishing, Strasbourg, pp 115-139. ISBN 92-871-5090-7
21. Dolan K, Rutter S, Wodak A (2003) Prison-based syringe exchange programmes: a review of international research and development Addiction 98:153-158
22. Aceijas C, Stimson GV, Hickman M, Rhodes T (2004) Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18:2295-2303
23. Poschadel S, Höger R, Schnitzler J, Schreckenberg D (2003) Evaluation der Arbeit der Drogenkonsumräume in der Bundesrepublik Deutschland. Schriftenreihe des Bundesministeriums für Gesundheit und Soziale Sicherheit, Band 149, Nomos, Baden-Baden
24. Marcus U, Starker A (2006) Gesundheitsberichterstattung des Bundes. Heft 31, HIV und AIDS. Robert Koch-Institut, Berlin
25. Wittchen HU, Apelt S (2006) Methadon- und Buprenorphinbehandlung in der Routineversorgung: Ergebnisse der deutschlandweiten COBRA-Studie von 2694 Patienten. Suchtmed 8(2):74